Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Patients with Multiple Sclerosis Attempting Conception: Interim Analysis from PREG-MS and CANPREG-MS Prospective Pregnancy Registries.
Multiple Sclerosis
P9 - Poster Session 9 (5:30 PM-6:30 PM)
12-009

MS is the most common inflammatory demyelinating neurological disorder affecting adults of reproductive age. This study emerged in response to an increasing need of women with MS for evidence-based, up-to-date, and personalized information surrounding reproductive issues.

To assess the effects of multiple sclerosis (MS) on achieving pregnancy in patients undergoing conception attempts.

Data were collected prospectively through two longitudinal, observational studies: (1) PREG-MS: New England MS Pregnancy Registry (USA) and (2) CANPREG-MS: Canadian Multiple Sclerosis Pregnancy Study. Both studies used similar data questionnaires and were conducted by phone interviews at specific time intervals during the pregnancy planning period, gestation and postpartum. The primary outcome was “pregnancy achieved.” DMT pregnancy exposure was defined according to respective FDA drug labels.

129 women with MS were enrolled during pregnancy planning (59 from PREG-MS; 70 from CANPREG-MS).  The two study groups were matched by age at MS onset, disease duration and disease subtype.  At the cut-off date, there were a total of 102 conceptions resulting in 75 viable pregnancies (73.5%) and 27 pregnancy losses (26.5%). Of the 102 pregnancies, 29 were exposed to DMT (28.4%) and 14 (13.7%) used assisted reproductive technology (ART). 58.4% pregnancies were achieved within 6 months.  There was no correlation between DMT exposure and 1) conception resulting in a viable pregnancy 2) miscarriage 3) duration of conception attempts (P > 0.05).

Fewer women with MS achieved pregnancy within 6 months compared to the general population (58.4% vs 75% from the general population).  Recent retrospective studies have also suggested a higher rate of infertility in MS patients. Larger studies are needed to assess effect of MS on achieving viable pregnancy and effects of extended conception attempts or varied pregnancy outcomes on MS. PREG-MS and CANPREG-MS are ongoing studies and additional data will be reviewed as applicable.

Authors/Disclosures
Maria K. Houtchens, MD
PRESENTER
Dr. Houtchens has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Houtchens has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche . Dr. Houtchens has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Houtchens has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Serono. Dr. Houtchens has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Cravath. Dr. Houtchens has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Beasley . Dr. Houtchens has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Biogen. The institution of Dr. Houtchens has received research support from Genzyme. The institution of Dr. Houtchens has received research support from Biogen. The institution of Dr. Houtchens has received research support from Genentech.
Preksha Kukreja, Other (Brigham and Women's Hospital) Ms. Kukreja has nothing to disclose.
Irene Yee, Other (University of British Columbia) Ms. Yee has nothing to disclose.
Jeta Pol-Patil, Research Assistant (Brigham and Women's hospital, Harvard Medical School.) Ms. Pol-Patil has nothing to disclose.
Adele Sadovnick, PhD (University of BC) Dr. Sadovnick has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Sadovnick has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sonofi. The institution of Dr. Sadovnick has received research support from Biogen MA.